This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Joint Center for Biosciences, Mogam Institute for Biomedicak Research. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 4 
1 out of 1 Years Active: 2022
Title: Hyeon Jin Kim: Innovator in TGF-beta Research
Introduction
Hyeon Jin Kim is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of biomedicine, particularly in the development of designer ligands for the TGF-beta superfamily. His innovative work has implications for various biological pathways and therapeutic applications.
Latest Patents
Hyeon Jin Kim holds a patent for "AB6 family designer ligands of TGF-beta superfamily." This patent describes a non-naturally occurring chimeric polypeptide that possesses activity provided by a TGF-beta family member. The chimeric polypeptide comprises two or more domains or fragments from parental TGF-beta proteins, operably linked to modulate pathways associated with TGF-beta family members. Specifically, the pathways targeted include the SMAD or DAXX pathways.
Career Highlights
Throughout his career, Hyeon Jin Kim has worked at prominent research institutions, including the Mogam Institute for Biomedical Research and the Joint Center for Biosciences. His work at these institutions has allowed him to explore innovative solutions in biomedicine and contribute to the advancement of scientific knowledge.
Collaborations
Hyeon Jin Kim has collaborated with notable colleagues, including Sen Yon Choe and Chi Hoon Ahn. These collaborations have fostered a productive research environment, leading to advancements in their respective fields.
Conclusion
Hyeon Jin Kim's contributions to the field of TGF-beta research exemplify the impact of innovative thinking in biomedicine. His patent and collaborative efforts highlight the importance of interdisciplinary work in advancing scientific understanding and therapeutic development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile